EGF receptor-targeted nanocarriers for enhanced cancer treatment

Nanomedicine

Volumn 7, Issue 12, 2012, Pages 1895-1906

  Master, Alyssa M ^a   Sen Gupta, Anirban ^a,b  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

antibody; antibody fragment; aptamer; cancer nanomedicine; EGF; EGF receptor targeting; peptide

Indexed keywords

APTAMER; CARMUSTINE; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOSOME; NANOCARRIER; OLIGONUCLEOTIDE; PACLITAXEL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB;

CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL DEATH; COLON CANCER; DRUG APPROVAL; DRUG CONJUGATION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; KIDNEY CANCER; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84871344885     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.160     Document Type: Review

References (88)

1. Keereweer S, Sterenborg HJ, Kerrebijn JD, Van Driel PB, de Jong RJ, Löwik CW. Image-guided surgery in head and neck cancer: current practice and future directions of optical imaging. Head Neck 34(1), 120-126 (2012).
2. Oh DS, Kirkpatrick JP. Targeted radiotherapy for malignant gliomas. Curr. Drug Discov. Technol. 9(4), 268-279 (2012).
3. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed. 4, 1-7 (2009).
4. Hoang B, Lee H, Reilly RM, Allen C. Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/ CT imaging. Mol. Pharm. 6(2), 581-592 (2009).
5. Lurje G, Lenz H-J. EGFR signaling and drug discovery. Oncology 77(6), 400-410 (2009).
6. Pan J, Feng SS. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials 30(6), 1176-1183 (2009).
7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46, 6387-6392 (1986).
8. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207 (2001).
9. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136-151 (2011).
10. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 6(1), 12-21 (2010).
11. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59(8), 748-758 (2007).
12. Cavallaro U, Christofori G. Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann. NY Acad. Sci. 1014(1), 58-66 (2004).
13. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 14(3), 295-304 (2007).
14. Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat. Res. 139, 135-152 (2008).
15. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. 27(6), 684-694 (2005).
16. Gridelli C, Maione P, Bareschino MA et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res. 30(4), 1301-1310 (2010).
17. Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol. Cancer 8, 94 (2009).
18. Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 32(12), 3340-3350 (2011).
19. Sandoval MA, Sloat BR, Lansakara-P DSP et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J. Control Release 157(2), 287-296 (2011).
20. Wang X, Zhu J, Zhao P et al. In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells. Cancer Biol. Ther. 6(6), 980-987 (2007).
21. Liao C, Sun Q, Liang B, Shen J, Shuai X. Targeting EGFR-overexpressing tumor cells using cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur. J. Radiol. 80(3), 699-705 (2011).
22. Kim IY, Kang YS, Lee DS et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control Release 140(1), 55-60 (2009).
23. Liu P, Li Z, Zhu M et al. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J. Mater. Sci. Mater. Med. 21(2), 551-556 (2010).
24. Noh T, Kook YH, Park C et al. Block copolymer micelles conjugated with anti- EGFR antibody for targeted delivery of anticancer drug. J. Polym. Sci., Part A Polym. Chem. 46(22), 7321-7331 (2008).
25. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30(29), 5737-5750 (2009).
26. Aggarwal S, Yadav S, Gupta S. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J. Biomed. Nanotechnol. 7(1), 137-138 (2011).
27. Zhang XQ, Lam R, Xu X, Chow EK, Kim HJ, Ho D. Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv. Mater. 23(41), 4770-4775 (2011).
28. Curry AC, Crow M, Wax A. Molecular imaging of epidermal growth factor receptor in live cells with refractive index sensitivity using dark-field microspectroscopy and immunotargeted nanoparticles. J. Biomed. Opt. 13(1), 014022 (2012).
29. Durr NJ, Larson T, Smith DK, Korgel BA, Sokolov K, Ben-Yakar A. Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods. Nano Lett. 7(4), 941-945 (2007).
30. Park C, Youn H, Kim H et al. Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug. J. Mater. Chem. 19(16), 2310-2315 (2009).
31. Ma LL, Tam JO, Willsey BW et al. Selective targeting of antibody conjugated multifunctional nanoclusters (nanoroses) to epidermal growth factor receptors in cancer cells. Langmuir 27(12), 7681-7690 (2011).
32. Kale A, Kale S, Yadav P et al. Magnetite/ CdTe magnetic-fluorescent composite nanosystem for magnetic separation and bio-imaging. Nanotechnology 22(22), 225101 (2011).
33. Wu Y, Chu M, Shi B, Li Z. A novel magneto-fluorescent nano-bioprobe for cancer cell targeting, imaging and collection. Appl. Biochem. Biotechnol. 163(7), 813-825 (2011).
34. Skala MC, Crow MJ, Wax A, Izatt JA. Photothermal optical coherence tomography of epidermal growth factor receptor in live cells using immunotargeted gold nanospheres. Nano Lett. 8(10), 3461-3467 (2008).
35. Wang J, Boriskina SV, Wang H, Reinhard BM. Illuminating epidermal growth factor receptor densities on filopodia through plasmon coupling. ACS Nano 5(8), 6619-6628 (2011).
36. Jokerst JV, Miao Z, Zavaleta C, Cheng Z, Gambhir SS. Affibody- functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor. Small 7(5), 625-633 (2011).
37. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239(1), 129-135 (2006).
38. Melancon MP, Lu W, Yang Z et al. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol. Cancer Ther. 7(6), 1730-1739 (2008).
39. Melancon MP, Lu W, Zhong M et al. Targeted multifunctional gold-based nanoshells for magnetic resonance-guided laser ablation of head and neck cancer. Biomaterials 32(30), 7600-7608 (2011).
40. Pan X, Lee RJ. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int. J. Pharm. 336(2), 276-283 (2007).
41. Yang J, Lee J, Kang J et al. Smart drug-loaded polymer gold nanoshells for systemic and localized therapy of human epithelial cancer. Adv. Mater. 21(43), 4339-4342 (2009).
42. Berlin JM, Pham TT, Sano D et al. Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery. ACS Nano 5(8), 6643-6650 (2011).
43. Patra C, Cao S, Safgren S. Intracellular fate of a targeted delivery system. J. Biomed. Nanotechnol. 4, 508-514 (2008).
44. Löw K, Wacker M, Wagner S, Langer K, von Briesen H. Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells. Nanomedicine 7(4), 454-463 (2011).
45. Liu D, Chen C, Hu G et al. Specific targeting of nasopharyngeal carcinoma cell line CNEl by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging. Acta. Biochim. Biophys. Sin. 43(4), 301-306 (2011).
46. Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R. Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study. Int. J. Nanomed. 6, 2859-2864 (2011).
47. Cherukuri P, Curley SA. Cancer nanotechnology. In: Cancer Nanotechnology, Methods in Molecular Biology. Grobmyer SR, Moudgil BM (Eds). Humana Press, NJ, USA, 359-373 (2010).
48. Peng X-H, Wang Y, Huang D et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano. 5(12), 9480-9493 (2011).
49. Yang L, Mao H, Wang YAA et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5(2), 235-243 (2009).
50. Mamot C, Drummond DC, Greiser U et al. Epidermal growth factor receptor (EGFR)- targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63(12), 3154-3161 (2003).
51. Talelli M, Iman M, Rijcken CJF, van Nostrum CF, Hennink WE. Targeted core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. J. Control. Release 148(1), e121-e122 (2010).
52. Talelli M, Rijcken CJF, Oliveira S et al. Reprint of "Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". J. Control. Release 153(1), 93-102 (2011).
53. Tseng CL, Wu SY, Wang WH et al. Targeting efficiency and biodistribution of biotinylated- EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 29(20), 3014- 3022 (2008).
54. Tseng CL, Wang TW, Dong GC et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28(27), 3996-4005 (2007).
55. Shimada T, Ueda M, Jinno H et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 29(4), 1009-1014 (2009).
56. Fonge H, Lee H, Reilly RM, Allen C. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy. Mol. Pharmaceutics. 7(1), 177-186 (2009).
57. Creixell M, Herrera AP, Ayala V et al. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J. Magn. Magn. Mater. 322(15), 2244-2250 (2010).
58. Zhang Z, Chen J, Ding L et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6(3), 430-437 (2010).
59. Jin H, Lovell JF, Chen J et al. Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging. Cancer Nanotechnol. 1(1-6), 71-78 (2010).
60. Tam N, Scott B, Wilson B. Lung cancer targeted Raman active phospholipid gold nanoparticles for ultrasensitive and specific molecular imaging and detection. Proc. SPIE 8090, Novel Biophotonic Techniques and Applications, 80900A (2011).
61. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9(7), 537-550 (2010).
62. Li N, Larson T, Nguyen HH, Sokolov KV, Ellington AD. Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. 46(3), 392-394 (2010).
63. Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J. Control. Release 157(2), 279-286 (2012).
64. Xu J, Amiji M. Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles. J. Vis. Exp. 4(59), e3612 (2011).
65. Yuan Y, Paunesku T, Arora H, Ward J, Vogt S, Woloschak G. Interrogation of EGFR-targeted uptake of TiO2 nanoconjugates by x-ray fluorescence microscopy. In: Tenth International Conference on X-Ray Microscopy McNulty I, Eyberger C, Lai B (Eds). American Institute of Physics, NY, USA, 423-426 (2011).
66. Song S, Liu D, Peng J et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB 23(5), 1396-404 (2009).
67. Li Z, Zhao R, Wu X et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19(14), 1978-1985 (2005).
68. Song S, Liu D, Peng J et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 363(1-2), 155-161 (2008).
69. Magadala P, Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 10(4), 565-76 (2008).
70. Milane L, Duan Z, Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS ONE 6(9), e24075 (2011).
71. Milane L, Duan Z, Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm. 8(1), 185-203 (2011).
72. Milane L, Duan Z-F, Amiji M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine 7(4), 435-444 (2011).
73. Master AM, Rodriguez ME, Kenney ME, Oleinick NL, Sen Gupta A. Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies. J. Pharm. Sci. 99(5), 2386-2398 (2010).
74. Master AM, Qi Y, Oleinick NL, Sen Gupta A. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine 8(5), 655-664 (2012).
75. Herbst R. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 94(5), 1593-1611 (2002).
76. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
77. Kaufman, Howard L. Molecular Targeting in Oncology. (1st Edition). Wadler S, Antman K, (Eds). Humana Press, NJ, USA (2008).
78. Bristol-Myers Squibb. Erbitux® product insert (2004).
79. Patel D, Lahiji A, Patel S et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 27(5A), 3355-3366 (2007).
80. Hadjipanayis CG, Machaidze R, Kaluzova M et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70(15), 6303-6312 (2010).
81. Jiang H, Wang H, Tan Z et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J. Biol. Chem. 286(7), 5913-5920 (2011).
82. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int. J. Cancer 101(6), 567-575 (2002).
83. Zhou Y, Drummond DC, Zou H et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol. 371(4), 934-947 (2007).
84. Roovers RC, Vosjan MJ, Laeremans T et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int. J. Cancer 129(8), 2013-2024 (2011).
85. Swindle CS. Epidermal growth factor (EGF)- like repeats of human tenascin-C as ligands for EGF receptor. J. Cell. Biol. 154(2), 459-468 (2001).
86. National Cancer Institute. Cancer of all sites - SEER Stat Fact Sheets (2011). http://seer.cancer.gov/statfacts/html/all.html
87. US FDA. Doxil drug details (2012). www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?useaction=Search. DrugDetails
88. US FDA. Abraxane: drug approval package. www.accessdata.fda.gov/ drugsatfda-docs/ nda/2005/21660-AbraxaneTOC.cfm